Children with cancer tumors lacking DNA repair may benefit from olaparib combined with ceralasertib.

Published Date: 19 Apr 2023

Pediatric patients with solid tumors exhibiting DNA replication stress and/or DNA repair responded favorably to a combination of the investigational ATR inhibitor ceralasertib and the PARP inhibitor olaparib (Lynparza).

Read Full News

Latest News



Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Study supports routine brain MRI screening in asymptomatic late-stage breast cancer patients

2.

Preferred and Actual Location of Death Often Don't Match for Young Cancer Patients

3.

Childhood cancer survivors face new health problems later in life, study shows

4.

In Hemophilia A and B, a Novel Monoclonal Antibody Reduces Bleeding.

5.

In 18 States, alcohol exclusion laws are still in effect.


© Copyright 2025 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot